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Abstract
Introduction: Identification of persons living with human immunodeficiency virus (HIV)-associated tuberculosis (TB) at
increased risk for unfavourable TB outcomes would inform efforts to improve such outcomes. We sought to identify factors
associated with a decreased risk of unfavourable TB treatment outcomes among people living with HIV-infection (PLHIV) in
low- and middle-income countries (LMIC), with a specific focus on directly observed therapy (DOT) compared with self-admin-
istered therapy (SAT) during the continuation phase of anti-TB therapy.
Methods: We conducted a retrospective cohort study among adults diagnosed with HIV-associated TB in Africa, Asia and the
Americas from 2012 to 2013; data were collected from 2012 to 2016. Unfavourable TB treatment outcomes (death during
TB treatment, and TB treatment failure or recurrence) were defined according to World Health Organization criteria. Receipt
of DOT was obtained at the site level and defined as ≥5 days of DOT per week. The person administering DOT and treatment
location varied by site. Lack of receipt of DOT was defined as SAT. Multivariable logistic regression estimated the adjusted
odds of unfavourable TB treatment outcomes.
Results: Among 1862 adults with HIV-associated TB included, 252 (13.5%) had unfavourable TB outcomes (226 deaths, 26
recurrences/failures). Overall, 1825 (98%) received DOT in the intensive phase and 1617 (87%) received DOT in the continua-
tion phase. DOT in the continuation phase was not significantly associated with unfavourable TB outcomes (aOR 1.43, 95% CI
0.86 to 2.38) compared to SAT. Body mass index (BMI) change during anti-TB treatment (per 2 units increase, aOR 0.74, 95%
CI 0.68 to 0.82) and CD4+ count at TB diagnosis (200 vs. 50 cells/µL, aOR 0.54, 95% CI 0.39 to 0.73) were both indepen-
dently associated with decreased odds of unfavourable TB treatment outcomes.
Conclusions: In this large, international cohort of people living with HIV-associated TB in LMIC who received intensive phase
DOT, DOT during the continuation phase of anti-TB therapy was not associated with a decreased odds of unfavourable TB
treatment outcomes compared to SAT. Randomized trials evaluating the effect of continuation-phase DOT on TB outcomes
among PLHIV are needed.
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1 | INTRODUCTION
Tuberculosis (TB) remains a serious public health problem,
particularly among people living with human immunodeficiency
virus (PLHIV). TB is the leading cause of death among PLHIV
worldwide, and people with HIV-associated TB have higher
rates of other unfavourable TB treatment outcomes, including
TB recurrence or TB treatment failure, that require re-treat-
ment. In 2016, TB treatment success rates were 82% overall
but only 77% for HIV-associated TB [1]. TB re-treatment, in
turn, is associated with even higher rates of unfavourable TB
treatment outcomes (including death, recurrence and failure)
[2,3], drug resistance [4,5], and more complicated and costly
drug regimens.
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Standard therapy for patients without a prior history of TB
consists of a 2-month intensive phase including isoniazid,
rifampicin, pyrazinamide and ethambutol (HRZE) followed by a
4-month continuation phase including isoniazid and rifampicin
(HR) [6]. Suboptimal adherence has been associated with unfa-
vourable TB treatment outcomes [7] and the World Health
Organization’s End TB Strategy emphasizes patient-centred
treatment supervision [8]. Therefore, directly observed ther-
apy (DOT) has been considered the standard of care for TB
treatment, regardless of HIV status [9]. However, two previ-
ous systematic reviews [10,11] and one meta-analysis [12] did
not reveal an association between DOT and decreased risk of
TB recurrence or failure compared to self-administered ther-
apy (SAT). Most studies included in these analyses either
excluded HIV-positive persons or only included participants
with unknown HIV test results.
While DOT in the two-month intensive phase is associated
with a decreased risk of TB relapse [13], we are unaware of
studies assessing the effect of DOT specifically during the
longer continuation phase of therapy. DOT is often not pro-
vided in low- and middle-income countries (LMIC) [14] as it is
less feasible due to limited staffing, increased cost and trans-
portation difficulties compared to higher income countries.
The objective of this study was to identify factors associated
with unfavourable TB treatment outcomes including mortality,
TB treatment failure and recurrence among PLHIV in a large,
international cohort collaboration. We specifically sought to
determine if DOT during the continuation phase of therapy
was associated with a decreased risk of unfavourable TB
treatment outcomes compared to SAT.
2 | METHODS
2.1 | Study population
We conducted a retrospective cohort study among PLHIV aged
≥16 years from the International Epidemiology Studies to Eval-
uate AIDS (IeDEA) cohort collaboration (http://www.iedea.org/
), a consortium of ART treatment programmes predominantly
established in low- and middle-income countries (LMIC). Sites
were located in 18 countries and included a mix of healthcare
facility types: referral hospitals, regional hospitals and primary
care facilities. Consecutive participants were included if they
were diagnosed with HIV-associated TB between 1 January
2012 and 31 December 2013. Patients were followed until
death, TB failure/recurrence or administrative censoring on 31
December 2014 in order to capture ≥12 months of follow-up
per individual. Patients who died within eight weeks of TB diag-
nosis were excluded as it may not have been possible to initiate
ART within eight weeks, an important covariate of interest.
Patients were excluded if they had documented resistance to
isoniazid or rifampicin, were not initiated on the standard
HRZE regimen for patients without a prior history of TB, or
had unevaluable TB treatment outcomes (Figure 1).
2.2 | Ethical considerations
Independent Ethics Committee (IEC) or Institutional Review
Board (IRB) approval for this study was obtained by each
of the local IeDEA sites as well as coordinating centres (see
Data S1).
2.3 | Data collection
A standardized case report form (CRF) designed for this study
was used to collect data on patient demographics, vital status,
laboratory data, TB treatment regimens and TB treatment
outcomes. The CRF was developed in Research Electronic
Data Capture (REDCap) and was available in English, French
and Spanish [15]. Local IeDEA site investigators completed a
CRF for each TB case after medical record review from Jan-
uary 2012 to January 2016. Routine data audits for quality
assurance were completed by the principal investigator (PI).
Information on ART initiation dates were obtained from the
electronic regional IeDEA data repositories.
2.4 | Study definitions
TB case definitions and treatment outcomes were defined
according to WHO definitions [16]. Our primary outcome of
interest was a composite unfavourable endpoint of death dur-
ing TB treatment and TB treatment failure or recurrence, as
both of the latter two endpoints would result in the need for
TB re-treatment. TB recurrence was defined as re-initiation of
therapy for a diagnosis of TB following a TB episode with an
outcome of cure or treatment completion. TB cure was
defined as a case of bacteriologically confirmed TB at the
beginning of treatment with negative smears or cultures in
the last month of treatment and on ≥1 previous occasion. TB
treatment completion was defined as a case for whom treat-
ment was completed, but without record of smear or culture
results. TB treatment failure was defined as a TB case for
whom sputum smear or culture was positive at five months or
later during TB treatment. Unevaluable TB treatment out-
comes included those lost to follow-up or without an assigned
TB treatment outcome.
Our primary exposure of interest was receipt of TB treat-
ment by DOT during the entire continuation phase of therapy.
DOT data were obtained at the site-level and applied to each
individual patient receiving care at the site. Receipt of DOT
was defined as ≥5 days of DOT per week; <5 days of DOT
was defined as SAT. DOT was defined according to local
guidelines with respect to the person administering therapy
(family member/friend vs. healthcare worker) and the location
of treatment (home/community-based vs. healthcare facility-
based).
Covariates identified for inclusion in multivariable models a
priori included age at TB diagnosis, sex, baseline body mass
index (BMI), change in BMI from the date of anti-TB treat-
ment start to the date of anti-TB treatment stop, smear sta-
tus, culture status, bacteriologic TB confirmation, site of
disease (extrapulmonary, pulmonary/both/unknown), CD4+
count at TB diagnosis, IeDEA region, year of TB diagnosis and
ART initiation timing in relation to TB diagnosis. Bacteriologi-
cally-confirmed disease was defined as a positive acid fast
bacillus (AFB) smear, culture, Xpert MTB/RIF or other nucleic
acid amplification test (NAAT). Extrapulmonary TB (EPTB) was
defined as a case of TB involving organs other than the lungs.
Pulmonary TB (PTB) was defined as a case of TB involving the
lung even when extrapulmonary disease was also present [1].
The CD4+ lymphocyte count at TB diagnosis was defined as
the nearest available value 180 days before or up to 30 days
after the date of TB diagnosis.
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ART was defined as ≥3 antiretroviral drugs including nucle-
oside reverse transcriptase inhibitors (NRTIs), protease inhi-
bitors (PIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), or integrase inhibitors. Early ART initiation was
defined as initiation within eight weeks of TB diagnosis. This
ART initiation timing cutoff was chosen to be consistent with
the WHO guidelines recommending ART initiation within
eight weeks of TB diagnosis dating back to 2009 [6]. TB
diagnosis date was defined as the date of anti-TB therapy
initiation.
2.5 | Statistical analysis
Categorical and continuous variables were compared using
the chi-squared and Wilcoxon rank sum tests respectively. The
association of DOT with the composite outcome was assessed
using unadjusted and adjusted logistic regression in order to
estimate the odds of unfavourable TB outcomes compared to
SAT. Continuous predictor variables were modelled using
restricted cubic splines with three knots. Covariates with
missing data (excluding missing data for the combined primary
outcome) were imputed once using predictive mean matching
[17]. Subjects with missing outcome data were assumed to
have been alive and event free until the end of follow-up. All
p-values were two-sided and considered statistically significant
if <0.05. R version 3.4.2 (www.r-project.org) was used for
analysis and analysis scripts are available online (http://biostat.
mc.vanderbilt.edu/ArchivedAnalyses).
2.6 | Sensitivity analyses
We identified a priori two important sensitivity analyses to
perform. In the first, we explored the most conservative
assumption that all persons with missing vital status had died.
In the second, only participants with baseline CD4+ counts
<50 cells/µL who survived at least two weeks after TB diag-
nosis were included, and the ART initiation timing covariate
cutoff was changed from eight weeks to two weeks. This sen-
sitivity analysis was done to be consistent with results of the
STRIDE study which demonstrated that ART initiation within
two weeks of TB diagnosis for patients with HIV-associated
TB and a baseline CD4+ count <50 cells/µL was associated
with a lower rate of AIDS defining illnesses and death [18].
For the second sensitivity analysis, inverse probability
weighted propensity score methods [19] were utilized rather
than standard logistic regression to avoid overfitting the mod-
els due to a low event rate. We adjusted for confounders by
weighting observations using inverse probability weights
(IPW); specifically, the inverse of the probability of the
observed exposure level given the observed values of covari-
ates (confounders). Weighting by this inverse probability cre-
ated a pseudo-population in which the covariates of interest
were balanced. We performed this analysis for our primary
exposure of interest (DOT) as well as our other covariates of
interest.
Standardized mean difference (SMD) plots [20] were used
to assess the appropriateness of the weights. Standardized
Consecutive HIV-Associated TB Cases among 
Participants ≥16 years of age Initiating 
Standard HRZE anti-TB therapy 
N = 2264 
Eligible HIV-Associated TB 
Cases 
N = 1862 
Exclusions (N = 402) 
Known INH or RIF drug resistance (N = 11) 
Death within 8 weeks of TB treatment initiation 
(N = 105) 
Unevaluable (N = 286) 
Continuation Phase DOT 
N = 1617 (87%) 
Continuation Phase SAT 
N = 245 (13%) 
Unfavorable TB Outcome 
N = 228 (14%) 
Favorable TB Outcome 
N = 1389 (86%) 
Unfavorable TB Outcome 
N = 24 (10%) 
Favorable TB Outcome 
N = 221 (90%) 
Figure 1. Flow diagram describing the study population.
DOT, directly observed therapy; HIV, human immunodeficiency virus; HRZE, isoniazid/rifampicin/pyrazinamide/ethambutol; SAT, self-administered
therapy; TB, tuberculosis.
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difference in means was used to compare balance in mea-
sured variables between exposed and unexposed subjects. For
continuous exposures, the groups were divided at the median
to calculate SMDs; for >2 categories, the groups were divided
by the most prevalent versus the rest to calculate SMDs. An
SMD equal to 0.10 means that the difference in means is
within 10% of the pooled standard deviation.
3 | RESULTS
There were 1862 adults aged 16 years or older diagnosed
with HIV-associated TB included in this analysis. Participants
were from 18 countries in 5 IeDEA regions (Caribbean, Cen-
tral, and South America network for HIV epidemiology (CCA-
SAnet), Western Africa, Central Africa, Eastern Africa and the
Asia-Pacific) (Figure 2).
The clinical and demographic characteristics of the study
population are in Table 1. Overall, 252 (13.5%) adults with
HIV-associated TB developed unfavourable TB outcomes. This
included 226 deaths during TB treatment (12.1%) and 26 TB
recurrences or treatment failures (1.4%). Among 1351
(72.6%) PLHIV not on ART who survived at least eight weeks
after TB diagnosis, 477 (35%) were started on ART within
eight weeks and 874 (65%) were started on ART >8 weeks
after TB diagnosis or not started on ART before the end of
follow-up. PLHIV who had unfavourable TB treatment out-
comes were more likely to be older at the time of TB diagno-
sis (38 vs. 36 years, p = 0.012) and have lower median CD4+
counts at the time of TB diagnosis (74 vs. 123 cells/µL,
p < 0.001); they were less likely to gain weight over the
course of TB treatment (0 vs. 2 kg, p < 0.001). There were
also regional differences, with those who had unfavourable
treatment outcomes being more likely to reside in the CCA-
SAnet or Central and Eastern Africa regions (Table 1).
The details regarding DOT at each site with respect to the
number of days per week of DOT in the intensive phase, the
number of days per week of DOT in the continuation phase,
the person giving DOT, and the location of DOT are in Table 2.
There were 37 (2%) PLHIV in care at one site who did not
receive DOT during the intensive phase and 245 (13%) PLHIV
in care at seven sites who did not receive DOT during the
continuation phase of TB treatment. Only 13 (5%) of those
categorized as not receiving DOT during the continuation
phase of therapy (<5 days per week), received thrice weekly
DOT; the remainder (95%) did not receive any DOT during
the continuation phase of therapy.
In the adjusted models, continuation phase DOT was not
significantly associated with a decreased odds of unfavourable
TB treatment outcomes (aOR 1.43, 95% CI 0.86 to 2.38).
Both a higher CD4+ count at TB diagnosis (200 vs. 50 cells/
µL, aOR 0.54, 95% CI 0.39 to 0.73) and BMI increase during
anti-TB treatment (2 vs. 0 kg/mg2, aOR 0.74, 95% CI 0.68 to
0.82) were associated with a decreased odds of unfavourable
TB treatment outcomes in the multivariable model. There was
no association with the timing of ART initiation and TB treat-
ment outcomes among those not already on ART at the time
of TB diagnosis (Table 3).
In the first sensitivity analysis, 31 (1.7%) persons with miss-
ing vital status were assumed to have died and results were
largely unchanged (see Table S1). In the second sensitivity
analysis, 468 (25.1%) persons with CD4+ counts ≤50 cells/µL
at TB diagnosis were included (Table 4). Of the 364 persons
not on ART who survived at least two weeks after TB diagno-
sis, 49 (13%) were started on ART within two weeks of TB
diagnosis and 315 (87%) were started on ART >2 weeks after
TB diagnosis or not started on ART before the end of follow-
up. The adjusted model using IPW indicated a significant asso-
ciation between BMI change during anti-TB treatment and a
decreased odds of unfavourable TB treatment outcomes (aOR
0.60, 95% CI 0.49 to 0.73 for each 2 kg/m2 increase in BMI).
4 | DISCUSSION
In this study conducted within a large international HIV
cohort collaboration, DOT during the continuation phase of
TB treatment was not significantly associated with a
decreased odds of unfavourable TB treatment outcomes (TB
death, TB recurrence and TB treatment failure). Only 2% of
Figure 2. Adults with HIV-associated TB included in the study by IeDEA region and country.
Numbers in parentheses indicate the number of adults enrolled in each country.
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this study population did not receive intensive phase DOT. It
is possible that among a population with a very high frequency
of DOT in the intensive phase, that DOT during the continua-
tion phase does not affect TB treatment outcomes. There also
could have been confounding by indication – that persons at
increased risk of unfavourable TB treatment outcomes prefer-
entially received continuation phase DOT. A previous random-
ized trial conducted in Pakistan did not reveal an association
between DOT and TB outcomes when given only during the
intensive phase, compared to SAT throughout the entire
course of anti-TB treatment [21].
Several previous studies have attempted to evaluate the
impact of DOT on TB treatment outcomes but did not focus
on the population of PLHIV, did not focus on DOT in the con-
tinuation phase of anti-TB therapy, and did not use a compos-
ite endpoint of unfavourable TB treatment outcomes (death,
failure and recurrence). In three prospective studies (two con-
ducted in Thailand and one in Taiwan), DOT was shown to be
associated with a decreased risk of TB treatment default [22–
24] and increased rates of TB treatment cure [23,24]. One of
these studies also showed a trend towards a decreased risk
of TB treatment failure with DOT compared to SAT [23]. DOT
has not been shown to be associated with decreased risk of
TB relapse [25–27], although these studies were also limited
by low numbers of relapse events.
The rate of unfavourable TB treatment outcomes in this
population of persons with HIV-associated TB who survived at
least eight weeks was 13.5%; the TB mortality rate was
12.1% and the TB recurrence or treatment failure rate was
1.4%. Globally in 2017, the WHO estimated that the TB case
fatality rate among people living with HIV was 32.6%. More-
over it is estimated that 23% of TB notifications among PLHIV
had unfavourable treatment outcomes [1]. It is possible that
the rates of unfavourable outcomes in this population are
lower than global estimates because this population was
enrolled from a cohort of PLHIV who were in care in an ART
programme. It is also likely that the exclusion of persons who
Table 1. Demographic and clinical characteristics of the study
population
Unfavourable Favourable p-
value*(n = 252) (n = 1610)
Age at TB diagnosis,
median (IQR)
38 (32 to 45) 36 (30 to 43) 0.012
Female, n (%) 104 (41%) 669 (42%) 0.99
BMI at TB diagnosis
(kg/m2), median
(IQR)
18 (16 to 20) 19 (17 to 21) 0.013
Missing, n (%) 54 (21%) 312 (19%)
BMI change from TB
treatment start to
stop date, median
(IQR)
0 (1 to 1) +2 (1 to 3) <0.001
Missing, n (%) 139 (55%) 621 (39%)
AFB smear result, n (%)
Positive 72 (29%) 516 (32%) 0.10
Negative 109 (43%) 736 (46%)
Not performed 71 (28%) 357 (22%)
Missing 0 (0%) 1 (<1%)
AFB culture result, n (%)
Positive 16 (6%) 96 (6%) 0.58
Negative 14 (6%) 118 (7%)
Not performed 222 (88%) 1395 (87%)
Missing 0 (0%) 1 (<1%)
Bacteriologic Confirmation (smear, culture or NAAT positive), n (%)
Yes 80 (32%) 596 (37%) 0.12
No 172 (68%) 1014 (63%)
Site of disease, n (%)
Pulmonary 176 (70%) 1140 (71%) 0.31
Extra-pulmonary
only
66 (26%) 374 (23%)
Both 10 (4%) 82 (5%)
Unknown 0 (0%) 14 (1%)
Intensive phase DOT, n (%)
Yes 251 (100%) 1574 (98%) 0.09
No 1 (<1%) 36 (2%)
Continuation phase DOT, n (%)
Yes 228 (90%) 1389 (86%) 0.08
No 24 (10%) 221 (14%)
CD4+ count at TB
diagnosis, median
(IQR)
74 (26 to 197) 123 (45 to 262) <0.001
Missing, n (%) 46 (18%) 250 (16%)
ART status at TB diagnosis, n (%)
No 174 (69%) 1177 (73%) 0.90
Yes 56 (22%) 366 (22%)
Missing 22 (9%) 67 (4%)
ART initiation after TB diagnosis (excluding those already on ART), n
(%)a
>8 weeks 105 (60%) 769 (65%) 0.23
8 weeks or less 69 (40%) 408 (35%)
Table 1. (Continued)
Unfavourable Favourable p-
value*(n = 252) (n = 1610)
Region, n (%)
Asia-Pacific 14 (6%) 251 (16%) <0.001
CCASAnet 39 (15%) 129 (8%)
Central Africa 37 (15%) 248 (15%)
Eastern Africa 151 (60%) 885 (55%)
Western Africa 11 (4%) 97 (6%)
Year of TB diagnosis, n (%)
2012 140 (56%) 875 (54%) 0.77
2013 112 (44%) 735 (46%)
Percentages are calculated for non-missing data. AFB, acid fast bacilli;
ART, antiretroviral therapy; BMI, body mass index; DOT, directly
observed therapy; IQR, interquartile range; kg, kilogram; m, meter;
NAAT, nucleic acid amplification test; TB, tuberculosis.
aThe denominators for these percentages are the number of patients
not on ART at TB diagnosis.; *p-value is for the comparison of charac-
teristics of persons with and without unfavourable outcomes.
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died within the first eight weeks of TB treatment (n = 106,
32%) and/or the possibility that some deaths were missed
contributed to the lower TB mortality rate in this study popu-
lation.
The majority of patients not on ART at the time of TB diag-
nosis (65%) in our study who survived at least eight weeks
after TB diagnosis, were not started on ART within eight
weeks. Among those with CD4+ counts <50 cells/µL at TB
diagnosis, even a higher proportion who survived at least two
weeks after TB diagnosis (87%) were not started on ART
within two weeks. This finding is consistent with that of a pre-
vious study in South Africa, which found that only 51.1% initi-
ated ART within eight weeks of TB diagnosis. These data
suggest that barriers to expedited ART initiation exist and that
improved integration of TB and ART services may lead to
improvements in ART initiation delays [28].
We did not find an association with the timing of ART
initiation and TB treatment outcomes among those not
already on ART at the time of TB diagnosis. Several clinical
trials have shown that earlier ART initiation in relation to
TB diagnosis is associated with improved survival [18,29,30];
however, there are several significant differences between
those studies and our study. Only one of these trials, the
STRIDE study, allowed enrolment of persons with smear-
negative TB as our study did. The STRIDE study used a pri-
mary endpoint of AIDS-defining illness and death. Of their
116 endpoints, 63 (54%) were due to AIDS-defining ill-
nesses and 53 (46%) were due to death [18]. In contrast,
our study used a primary endpoint of TB recurrence or
treatment failure and death. Of our 252 endpoints, 26
(10%) were due to TB recurrence or treatment failure and
226 (90%) were due to death. It is possible that these dif-
ferences in eligibility criteria and primary outcome defini-
tions led to our differing findings with respect to the timing
of ART initiation.
An increase in BMI during TB treatment was associated
with a decreased risk of TB recurrence or treatment failure.
This finding is consistent with the findings from Tuberculosis
Trials Consortium Study 22 which found that participants
who were underweight at enrolment and had a <5% weight
gain over the intensive phase of anti-TB treatment had
nearly twice the risk of relapse compared to those who
gained more than 5% [31]. It is unclear if the association
between lack of weight gain and TB recurrence or treatment
failure is due to a poor response to anti-TB treatment stunt-
ing the rate of weight gain, or if the presence of adequate
weight gain is required in order for patients to respond
appropriately to anti-TB therapy. Regardless, the WHO rec-
ommends nutritional evaluation, counselling and support as
part of TB care [32].
The main limitation of this study is that we did not have
detailed data at the individual patient level with respect to
adherence either in the setting of DOT or SAT. Moreover we
did not have individual level data on the person administering
DOT (family member/friend vs. healthcare worker) or the
location of DOT (home/community-based vs. healthcare facil-
ity-based). However, a previous meta-analysis found no differ-
ence in TB treatment outcomes between community-observed
versus family-observed and between home-observed versus
healthcare facility-observed DOT [10]. Another limitation was
Table 2. Directly observed therapy details by site
Site Days per week IP Days per week CP Person giving DOT Location of DOT
Benin 7 0 HCW HCF
Brazil 5 5 HCW Home or HCF
Burundi 7 7 Family, friend, or HCW Home, community, or HCF
Cameroon 7 0 HCW Healthcare facility
Cote d’Ivoire 7 7 Family or friend Home or community
Honduras 6 3 Family, friend, or HCW Home, community, or HCF
Kenya 7 7 Family, friend, or HCW Home or HCF
Mali 7 7 Family, friend or HCW Home, community or HCF
Mexico 5, 6, or 7 5 HCW Home or HCF
Peru 5 or 6 5 HCW HCF
Philippines 7 7 Family, friend, or HCW Home, community, or HCF
Republique Democratique du Congo 6 0 HCW HCF
Rwanda 7 7 HCW Home, community, or HCF
Senegal 7 7 Family, friend, or HCW Home, community, or HCF
Tanzania-Kisesa 7 7 Family, friend, or HCW Home or HCF
Tanzania-Tumbi 7 0 HCW HCF
Thailand-HIV-NAT 5, 6, or 7 0 Family, friend, or HCW Community or HCF
Thailand-Ramathibodi Hospital 0 0 No DOT No DOT
Uganda 7 7 Family, friend, or HCW Home, community, or HCF
Vietnam-Bach Mai Hospital 7 7 Family, friend, or HCW HCF during IP and home during CP
Vietnam-NHTD 7 7 Family, friend, or HCW Home, community, or HCF
CP, continuation phase; HCF, healthcare facility; HCW, healthcare worker; HIV-NAT, The HIV Netherlands Australia Thailand Research Collabora-
tion; IP, intensive phase; NHTD, National Hospital for Tropical Diseases.
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that the number of TB recurrences and treatment failures
was low, which decreased the power of the study. While we
did not collect information regarding whether a smear and/or
culture at months 5 or later during TB treatment was per-
formed or not, we do know that 22% of cases did not have a
smear performed at any time during TB treatment and 86%
of cases did not have a culture performed at any time during
TB treatment. So, misclassification of TB treatment failure as
another outcome is possible due a lack of smear and/or cul-
ture for TB diagnosis. Additionally, it is possible that some of
the cases that transferred care to another facility or defaulted
may have actually had an unfavourable TB outcome including
death, recurrence or failure.
Moreover it is possible that some recurrent cases were not
identified during the 12-month follow-up. Two studies report-
ing combined results from TB treatment trials suggest that
12 months of follow-up is sufficient in order to capture most
TB recurrences [33,34]. However, it may take longer to iden-
tify recurrent TB cases in programmatic settings in which fol-
low-up is less active compared to clinical trials. Additionally, it
is possible that some patients moved out of the local IeDEA
site catchment area which would also contribute to under-
ascertainment of recurrent TB cases.
Another limitation was the lack of data on medical comor-
bidities known to be associated with unfavourable TB out-
comes. One important example, includes diabetes mellitus
(DM). In a recent systematic review, patients with TB and
comorbid DM had a higher odds of death and relapse [35].
Future studies evaluating the impact of factors associated
with unfavourable TB outcomes should include DM and other
important medical comorbidities.
5 | CONCLUSIONS
In this large, multi-centre, international study among individu-
als with HIV-associated TB who received intensive phase
DOT, we found that DOT given during the continuation phase
of TB treatment was not associated with a decreased odds of
unfavourable TB treatment outcomes. A higher CD4+ count at
TB diagnosis was independently associated with a decreased
odds of unfavourable TB treatment outcomes, highlighting the
need for early HIV testing and treatment. Increasing BMI dur-
ing anti-TB treatment was also associated with a decreased
odds of unfavourable TB treatment outcomes supporting the
importance of nutritional evaluation and support during anti-
TB therapy. Randomized trials evaluating the impact of DOT
during the continuation phase of therapy on TB outcomes
among PLHIV are needed.
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Table 3. Factors associated with Unfavourable TB Outcomes
(death, recurrence, failure)
Adjusted odds
ratio* (95% CI)
Age (years) 1.22 (0.99, 1.49)
Female sex 1.09 (0.81, 1.47)
Baseline BMI (kg/m2) 0.61 (0.42, 0.88)
BMI change (2 kg/m2 increase vs. no change) 0.74 (0.68, 0.82)
Smear positive 1.00 (0.42, 2.37)
Culture positive 1.28 (0.63, 2.61)
Bacteriologically confirmed 0.86 (0.36, 2.08)
Extrapulmonary versus pulmonary/both/unknown 1.18 (0.84, 1.66)
CD4+ cell count (200 vs. 50 cells/µL) 0.54 (0.39, 0.73)
ART status
On ART at TB diagnosis versus ART initiation
within eight weeks
1.08 (0.73, 1.58)
On ART at TB diagnosis versus ART after eight
weeks or never started on ART
1.25 (0.87, 1.80)
Continuation phase DOT 1.43 (0.86, 2.38)
Bold value indicates statistical significant (p < 0.05).
ART, antiretroviral therapy; BMI, body mass index; DOT, directly
observed therapy; TB, tuberculosis.
*The model was adjusted for all covariates in the table as well as year
of TB diagnosis and IeDEA region.
Table 4. Factors associated with unfavourable TB treatment
outcomes adjusted using Inverse Probability Weighting and
excluding those with CD4+ counts >50 cells/µL at TB diagnosis
(n = 1394, 74.9%)
IPW odds ratio*
(95% CI)
Age (40 vs. 30 years) 1.04 (0.71, 1.52)
Female versus male 0.86 (0.52, 1.42)
BMI change (2 kg/m2 increase vs. no change) 0.60 (0.49, 0.73)
Smear positive 0.61 (0.36, 1.05)
Culture positive 0.99 (0.21, 4.74)
Bacteriologically confirmed 0.69 (0.41, 1.17)
Extrapulmonary versus pulmonary/both/
unknown
1.13 (0.67, 1.91)
CD4+ cell count (30 vs. 10 cells/µL) 0.83 (0.57, 1.22)
ART status
On ART at TB diagnosis versus ART initiation
within two weeks
1.70 (0.73, 3.95)
On ART at TB diagnosis versus ART initiation
after two weeks
1.12 (0.54, 2.32)
Continuation phase DOT 1.07 (0.33, 3.50)
Bold value indicates statistical significant (p < 0.05).
ART, antiretroviral therapy; BMI, body mass index; DOT, directly
observed therapy; IPW, inverse probability weighting; TB, tuberculosis.
*Each summary is a separate model with IPW using all other factors.
For change in BMI, BMI at treatment initiation was included in the
inverse probability weighting model. In all models, IeDEA region and
year of diagnosis were included in the inverse probability weighting
model.
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